Adaptimmune Therapeutics PLC (ADAP)

[jondoeuk]

New preclinical data https://www.jimmunol.org/content/early/2021/12/01/jimmunol.2001357.long

GSK's GSK3845097 (one of three next-gen versions they both worked on together*), which co-expresses a dominant-negative TGF-ß type II receptor and targets NY-ESO-1 is in the clinic.

* So is another, the CD4+ T-cells co-express a CD8 co-receptor (again, it targets NY-ESO-1). The third isn't in the clinic, but it could overexpress PDE7A (increases resistance to both PGE2/adenosine and enhances apoptosis in target cells).